Details of Disease

General Information of Disease (ID: DISGSHOJ)

• Disease Name: Leishmania infection
• Disease Class: 1F54: Leishmaniasis
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISGSHOJ: Leishmania infection
• ICD Code:
  ICD-11: ICD-11: 1F54.0
  ICD-10: ICD-10: B55.0
• Disease Identifiers:
  MONDO ID: MONDO_0011989
  MESH ID: D007896
  UMLS CUI: C0023281
  MedGen ID: 9714
  Orphanet ID: 507
  SNOMED CT ID: 80612004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
WR-279396	DM479MZ	Phase 3	Small molecular drug	[1]
LEISH-F1	DMV2YDK	Phase 2	Vaccine	[2]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
KY-62	DM3WYCO	Terminated	Small molecular drug	[3]

This Disease is Treated as An Indication in 5 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GFC-001	DM1SOAK	Investigative	NA	[4]
GFC-036	DMDAYJM	Investigative	NA	[4]
ND-AMB	DMCSCQE	Investigative	NA	[4]
Oleylphosphocholine	DMN2JZT	Investigative	Small molecular drug	[4]
Oxaborole	DMY85EX	Investigative	NA	[4]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] ClinicalTrials.gov (NCT00606580) Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia). U.S. National Institutes of Health.
• [2] An overview on Leishmania vaccines: A narrative review article. Vet Res Forum. 2015 Winter;6(1):1-7.
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007623)
• [4] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.